98. Eosinophilic gastrointestinal disease Clinical trials / Disease details
Clinical trials : 171 / Drugs : 184 - (DrugBank : 47) / Drug target genes : 42 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03656380 (ClinicalTrials.gov) | March 20, 2019 | 30/8/2018 | Mepo for EoE Study | A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant Symptoms | EoE;Eosinophilic Esophagitis | Drug: Mepolizumab 300 mg;Drug: Mepolizumab 100 mg;Other: Placebo | University of North Carolina, Chapel Hill | GlaxoSmithKline;University of Utah;Northwestern University;MNGI Digestive Health, P.A. | Recruiting | 16 Years | 75 Years | All | 72 | Phase 2 | United States |